Tomorrow's Science For Today's Clinician
Collective results from recent clinical trials indicate that an oral drug called roxadustat is an effective treatment for anemia in patients with chronic kidney disease who do not require dialysis. The results were published in an upcoming issue of CJASN.
The mandatory internship for MBBS students proposed by National Medical Commission (NMC) in AYUSH streams has drawn sharp reactions from allopathic practitioners and students of modern medicine.
Professor Richard Haynes is the Clinical Coordinator for the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial which demonstrated that the investigational antibody combination casirivimab and imdevimab reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.
Aresearch team led by physicians of the Karl Landsteiner University of Health Sciences in Krems has identified a potential drug target to treat multiple myeloma (MM) by uncovering a pivotal role for a regulator protein.
A team of researchers from the Massachusetts Institute of Technology (MIT), is a private land-grant research university in Cambridge, has now developed an immunotherapy strategy of combining three drugs and has shown that it can eliminate pancreatic tumours in mice.
A team of researchers led by professor Rahul Purwar at the bioscience and bioengineering department of IIT-B have designed and developed the first indigenous CAR T-cell therapy in India.
A study published in the Journal of Clinical Oncology provides new insight into the genomic landscape of rhabdomyosarcoma and suggests that treatment stratification should integrate molecular features.
Researchers at UT Southwestern announced successful results of a clinical trial for a commonly prescribed weight-loss drug called liraglutide. The study was published in The Lancet Diabetes & Endocrinology.
An Imperial College London study found that fully vaccinated people in England were one-third as likely to test positive for COVID-19, according to their ongoing survey of the English population.
Most children who develop COVID-19 symptoms recover after six days, and a low percentage experience symptoms beyond four weeks, according to a large UK study published in the Lancet Child & Adolescent Health journal.